240
Kronik HCV
hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
15.
Fried MW, Shiffman ML, Reddy KR ve ark. Peginterferon alfa-2a plus ribavirin for
chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
16.
Jacobson IM, Mchutchison JG, Dusheiko G ve ark. Telaprevir for previously
untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
17.
Poordad F, Mccone J, JR., Bacon BR ve ark. Boceprevir for untreated chronic HCV
genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
18.
Kawamoto JK, Smith PJ, Han SB, Management of HCV Treatment-related Side-
effects, Toxicity, and Drug-interactions N A J Med Sci. 2014;7(1):33-37.
19.
Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple
therapy for hepatitis C virus. Gastroenterology 2012; 142:1314-1323.
20.
Gürbüz Y. Kronik hepatit tedavilerinde ilaca bağlı yan etki yönetimi Turkiye Klinikleri
J Inf Dis-Special Topics 2013;6(1):75-82.
21.
Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C.
Gastroenterology 2003; 124:1711-1719.
22.
Fried MW. Side effects of therapy of hepatitis C and their management.
Hepatology 2002; 36:S237.
23.
Hadziyannis SJ, Sette H, JR., Morgan TR ve ark. Peginterferon-alpha2a and
ribavirin combination therapy in chronic hepatitis C: a randomized study of
treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
24.
Sulkowski MS, Poordad F, Manns MP ve ark. Anemia during treatment with
peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease
inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57:974-984.
25.
Kwo PY, Lawitz EJ, Mccone J ve ark. Efficacy of boceprevir, an NS3 protease
inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-
naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label,
randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716.
26.
Rosch S, Johnen S, Mataruga A, Muller F, Pfarrer C, Walter P. Selective
photoreceptor degeneration by intravitreal injection of N-methyl-N-nitrosourea.
Invest Ophthalmol Vis Sci 2014; 55:1711-1723.
27.
Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin
Gastroenterol 2005; 39:S3-S8.
28.
Sulkowski MS. Management of the hematologic complications of hepatitis C
therapy. Clin Liver Dis 2005; 9:601-16, vi.
29.
Yee HS, Chang MF, Pocha C ve ark. Update on the management and treatment
of hepatitis C virus infection: recommendations from the Department of Veterans
Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Office. Am J Gastroenterol 2012; 107:669-689.
30.
Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of
anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a
(40KD) plus ribavirin. Am J Gastroenterol 2008; 103:1981-1988.
31.
Carreno V, Martin J, Pardo M ve ark. Randomized controlled trial of recombinant
human granulocyte-macrophage colony-stimulating factor for the treatment of
chronic hepatitis c. Cytokine 2000; 12:165-170.
32.
Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte
macrophage colony stimulating factor alone or in combination with interferon-
alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998; 28:382-389.
33.
Van Thiel DH, Faruki H, Friedlander L ve ark. Combination treatment of advanced
HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology
